The COVID stories that consume most of our attention concern its tragic death toll and the anxiety that pervades our efforts to respond to the threat, or even just live through it. But a global phenomenon also brings with it second-order effects—unanticipated “consequences of consequences” playing out in the background.
Patients frequently present with bothersome blepharoptosis, but in the absence of pharmacologic options, optometrists could historically do little to improve their appearance or functioning. However, late last year, the FDA accepted a promising New Drug Application that, if approved, may soon alter the landscape of ptosis care as we know it.
A 62-year-old Caucasian male presented to our office with concerns about his changing vision. Years before, he had a melanoma in his right eye, which was irradiated and treated with plaque therapy. He noted gradually changing vision in both eyes, and that prompted him to see another optometrist in the area earlier, but that doctor said that he “had too many things going on” and referred the case to a glaucoma surgeon. The patient found his way to me first, and it’s a good thing he did because, despite the many factors complicating his glaucoma, he wasn’t yet a surgical patient—so why send him to a surgeon?
You’ve taken the kids for their checkups and scheduled your parents’ doctor visits. You even went along to make sure they understand what was happening.
Nikki Iravani, OD, is always on the lookout for a great marketing tip.
Nine women ODs were honored during the fourth annual Theia Awards of Excellence from Women In Optometry magazine.